Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

This trial is conducted in Europe. The aim of this trial is to investigate whether the volume of water administered with NN9924 affects the anatomical location (stomach or proximal small bowel) of tablet erosion.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Novo Nordisk A/S

Criteria

Inclusion Criteria:

• Good general health

• Body mass index (BMI) of 18.5-30.0 kg/m^2 (both inclusive)

Exclusion Criteria:

• Males who are not willing to use two acceptable forms of highly effective contraception

• Participation in another clinical trial within 90 days

• Any chronic disorder or severe disease

• Use of GLP-1 (glucagon-like peptide-1) agonists within 3 months preceding dosing

• Subjects who are smokers

• Subjects who have donated any blood or plasma in the past month or in excess of 500 mL within the 12 weeks preceding screening